Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/7/2025

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Guillain-Barré Syndrome (GBS)

Introduction to CIDP and GBS

  • Approximately 5% of GBS patients develop acute-onset CIDP, typically within 8 weeks of GBS onset, characterized by three or more treatment-related fluctuations and clinical deterioration ≥8 weeks after disease onset, as supported by the American Academy of Neurology 1
  • CIDP can also develop as a distinct condition years after a resolved GBS episode, representing a new inflammatory demyelinating process, with a slightly higher risk of developing other immune-mediated neuropathies compared to the general population 1

Clinical Features of CIDP and GBS

  • Acute-onset CIDP is characterized by less severe symptoms than typical GBS, with patients often remaining able to walk, and rare need for mechanical ventilation, with CIDP-like electrophysiologic abnormalities 1
  • Late-onset CIDP after GBS can occur years after GBS resolution, with progressive symmetric weakness, sensory symptoms, diminished or absent reflexes, and lack of autonomic involvement 1
  • GBS typically follows a monophasic course with three distinct phases: Progressive phase, Plateau phase, and Recovery phase, with most extensive improvement occurring in the first year, and the modified Erasmus GBS outcome score (mEGOS) can help calculate an individual patient's probability of regaining walking ability 1

Diagnosis of CIDP

  • Electrophysiologic studies are essential for confirming demyelinating features, looking for conduction blocks, temporal dispersion, prolonged distal latencies, slowed conduction velocities, and prolonged F-wave latencies, as recommended by the American Academy of Neurology 1

Treatment of CIDP and GBS

  • First-line therapies for CIDP include intravenous immunoglobulin (0.4 g/kg daily for 5 days), corticosteroids, and plasma exchange as an alternative option, with maintenance therapy typically required, as supported by the American Academy of Neurology 1
  • The American Academy of Neurology recommends intravenous immunoglobulin and corticosteroids as first-line treatments for CIDP, with plasma exchange as an alternative option, and a multidisciplinary rehabilitation program is essential for optimal recovery in GBS, addressing not only weakness but also autonomic dysfunction, fatigue, proprioceptive sensory loss, and respiratory complications across all stages of recovery 1

Disease Course and Management

  • CIDP follows a chronic course requiring ongoing treatment, with regular neurological assessments to track disease progression, repeat electrodiagnostic studies to document demyelinating features, and assessment of treatment response and need for maintenance therapy, as recommended by the American Academy of Neurology 1
  • Most patients with Guillain-Barré Syndrome (GBS) show substantial recovery, with 60-80% regaining the ability to walk independently within 6 months after disease onset, though recovery can continue for more than 5 years after initial symptoms, and the mEGOS score can help predict outcomes 1
  • Mortality rate is 3-10% despite best medical care, with most deaths resulting from cardiovascular and respiratory complications, emphasizing the need for close monitoring and management of these complications, and common complications requiring management include respiratory failure, autonomic dysfunction, and fatigue, which affects 60-80% of patients and is often one of the most disabling residual complaints 1
  • Treatment-related fluctuations (TRFs) occur in 6-10% of patients, defined as disease progression within 2 months following initial treatment response, and may require additional treatment courses, while progression to chronic inflammatory demyelinating polyneuropathy (CIDP) occurs in ~5% of GBS patients, characterized by three or more TRFs and/or clinical deterioration ≥8 weeks after onset, and recurrent GBS episodes are rare but possible, occurring in 2-5% of patients, which is higher than the general population's lifetime risk (0.1%) 1

Rehabilitation and Management

  • A multidisciplinary rehabilitation program is essential for optimal recovery in GBS, including:
  • The primary goals of rehabilitation in GBS include preventing complications, maintaining range of motion, and managing respiratory function, with positioning the patient properly to prevent pressure sores and contractures, and performing passive range-of-motion exercises 2-3 times daily, and monitoring closely for dysautonomia, including blood pressure fluctuations and cardiac arrhythmias, and providing psychological support due to intact consciousness despite paralysis are also crucial 1